Reduced Reliance on Advisory Committees Raises Concerns

The Food and drug Administration (FDA) is moving to reduce its use⁢ of advisory committees – panels of external experts – when reviewing applications for new drugs. george Tidmarsh, MD, PhD, Director of the FDA’s Center for Drug Evaluation and Research, has indicated a preference for minimizing these committees, ‍characterizing them as “redundant” and placing an unneeded burden on both regulators and pharmaceutical companies.

A‍ Long-Standing ⁤Check on Agency Decisions

These advisory committees, formally established by law ⁤in 1972, have historically served as an crucial oversight mechanism⁣ for ⁢the FDA, particularly for drugs that are ⁣controversial or⁣ in ⁤high⁤ demand.They provide an independent assessment of a drug’s safety and efficacy before a final agency decision is made.

Concerns About Transparency and Informed Decision-Making

The⁣ shift in policy has⁤ drawn criticism from former FDA officials, academic leaders, and public health advocates. Robert Califf,MD,a former FDA Commissioner,expressed skepticism about the reasoning behind⁢ the change,stating that advisory commitee meetings are “extremely useful” ‍for internal FDA ⁢discussions and for ensuring the public⁢ understands the various perspectives considered ⁣during the drug approval process.

Critics argue that these meetings offer a crucial window into the FDA’s internal deliberations and help to inform more⁤ robust and transparent decision-making.

Decline in Advisory Committee Meetings

Data indicates‍ a⁤ significant reduction in the number of advisory committee meetings held under the current administration.⁣ only seven meetings were scheduled through 2025, compared to 22 during the same period in 2024. This decrease ‍reflects the agency’s ⁣evolving approach to drug approval and its diminished ⁢reliance on external expert input.